Literature DB >> 27507161

[Neuroendocrine neoplasms of the mediastinum].

L Brcic1, M Heidinger2, H Popper2.   

Abstract

Primary neuroendocrine tumors (NET) in the mediastinum are very rare and among them thymic NETs are the most common. They represent 5 % of all thymic and mediastinal tumors. The WHO classification from 2015 subdivides thymic NETs into three groups; low grade (typical carcinoid), intermediate grade (atypical carcinoid) and high grade (large cell neuroendocrine carcinoma and small cell carcinoma). Through this change of mediastinal/thymic NET classification into three groups of malignancy, the nomenclature was adapted to that of the lungs, while the histological criteria for each entity remained the same. Thymic NETs typically occur in middle-aged adults and predominantly in males. Approximately 30 % are asymptomatic and the rest present with symptoms caused by local tumor growth, distant metastases and/or endocrine manifestations. Carcinoids can also occur as a part of multiple endocrine neoplasia type 1 (MEN1) and at the time of diagnosis commonly present with regional lymph node or distant metastases, which most often affect the lungs and bones. For the correct diagnosis tumor cell morphology, mitotic count and/or necrosis are crucial. Patients with typical carcinoids have the best prognosis, whereas the prognosis is slightly worse for atypical carcinoids but very poor for large cell neuroendocrine carcinomas. Small cell carcinomas have the worst prognosis and the shortest median survival time of approximately 14 months.

Entities:  

Keywords:  Carcinoids; Cell morphology; Classification; MEN 1; Prognosis

Mesh:

Year:  2016        PMID: 27507161     DOI: 10.1007/s00292-016-0198-0

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  32 in total

1.  Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.

Authors:  William D Travis; Elisabeth Brambilla; Allen P Burke; Alexander Marx; Andrew G Nicholson
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

2.  Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series.

Authors:  P Ferolla; A Falchetti; P Filosso; P Tomassetti; G Tamburrano; N Avenia; G Daddi; F Puma; R Ribacchi; F Santeusanio; G Angeletti; M L Brandi
Journal:  J Clin Endocrinol Metab       Date:  2005-02-15       Impact factor: 5.958

3.  Tumor genetics and survival of thymic neuroendocrine neoplasms: a multi-institutional clinicopathologic study.

Authors:  Philipp Ströbel; Andreas Zettl; Konstantin Shilo; Wen-Yu Chuang; Andrew G Nicholson; Yoshihiro Matsuno; Anthony Gal; Rolf Hubert Laeng; Peter Engel; Carlo Capella; Mirella Marino; John Kwok-Cheung Chan; Andreas Rosenwald; William Travis; Teri J Franks; David Ellenberger; Inga-Marie Schaefer; Alexander Marx
Journal:  Genes Chromosomes Cancer       Date:  2014-04-25       Impact factor: 5.006

4.  Neuroendocrine differentiation in thymic epithelial tumors with special reference to thymic carcinoma and atypical thymoma.

Authors:  T Hishima; M Fukayama; Y Hayashi; T Fujii; K Arai; Y Shiozawa; N Funata; M Koike
Journal:  Hum Pathol       Date:  1998-04       Impact factor: 3.466

5.  Thymic neuroendocrine tumors: a SEER database analysis of 160 patients.

Authors:  Puja Gaur; Colleen Leary; James C Yao
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

6.  Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1.

Authors:  Fathia Gibril; Yuan-Jia Chen; David S Schrump; Alexander Vortmeyer; Zhengping Zhuang; Irina A Lubensky; James C Reynolds; Adeline Louie; Laurence K Entsuah; Kane Huang; Behnam Asgharian; Robert T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2003-03       Impact factor: 5.958

7.  Thymic carcinoma. A clinicopathologic study of 13 cases.

Authors:  L D Truong; D R Mody; P T Cagle; G L Jackson-York; M R Schwartz; T M Wheeler
Journal:  Am J Surg Pathol       Date:  1990-02       Impact factor: 6.394

8.  Neuroendocrine differentiation is a common feature of thymic carcinoma.

Authors:  L Lauriola; R A Erlandson; J Rosai
Journal:  Am J Surg Pathol       Date:  1998-09       Impact factor: 6.394

9.  A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus.

Authors:  Olivier Tiffet; Andrew G Nicholson; Georges Ladas; Mary N Sheppard; Peter Goldstraw
Journal:  Chest       Date:  2003-07       Impact factor: 9.410

10.  Large-cell neuroendocrine carcinoma in the thymus.

Authors:  Seiji Mega; Mitsuru Oguri; Ryosuke Kawasaki; Kazuaki Hazama; Kazuhiro Iwai; Satoshi Kondo
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-11-12
View more
  3 in total

1.  Atypical thymic carcinoid manifesting with nephrotic-range proteinuria in a 7-year-old boy.

Authors:  Jolanta Soltysiak; Danuta Ostalska-Nowicka; Katarzyna Zaorska; Karolina Sterzyńska; Katarzyna Derwich; Jacek Zachwieja
Journal:  Pediatr Nephrol       Date:  2017-05-05       Impact factor: 3.714

2.  Primary Mediastinal Small Cell Neuroendocrine Carcinoma Presenting with Superior Vena Cava Syndrome.

Authors:  Lina R Costanzo; Tariq Kewan; Kevin Kerwin; Hamed Daw
Journal:  Cureus       Date:  2019-06-10

3.  Long-term survival of a patient with an inoperable thymic neuroendocrine tumor stage IIIa under sole treatment with Viscum album extract: A CARE compliant clinical case report.

Authors:  María Reynel; Yván Villegas; Paul G Werthmann; Helmut Kiene; Gunver S Kienle
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.